A greater TIDE score suggests a higher probability of tumor immune escape and lower likelihood of benefitting from anti-PD-1/CTLA4 therapy (26), illustrating that low-risk patients are candidates for ICB therapy. Here, CTLA4 is linked to neoplasm.